A phase 1b, multicentre, dose escalation, safety and pharmacokinetics study of tilvestamab (BGB149) in relapsed, platinum-resistant, high-grade serous ovarian cancer (PROC) patients
Kenneth Sooi(National University Cancer Institute, Singapore), David S.P. Tan(National University of Singapore), Tuan Zea Tan(National University Cancer Institute, Singapore), David Micklem(BerGenBio (Norway)), Line Bjørge(Haukeland University Hospital), Akil Jackson(BerGenBio (Norway)), Jae‐Weon Kim(Seoul National University), Sarah P. Blagden(Churchill Hospital), Rebecca Kristeleit(Guy's and St Thomas' NHS Foundation Trust), Jung Y. Lee(Yonsei University), David J. Pinato(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Byoung-Gie Kim(Samsung Medical Center), Charlie Gourley(Edinburgh Cancer Research)
Cited by 2
Related Papers
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k
Association of Prior Antibiotic Treatment With Survival and Response to Immune Checkpoint Inhibitor Therapy in Patients With Cancer
|JAMA Oncology|2019|582
Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study
|The Lancet Oncology|2021|401